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Alloimmunization to red blood cell antigens is unpredictable 
and poorly understood. Patients who are negative for high-
incidence antigens (HIAs) are at risk for developing the 
corresponding antibodies. Molecular methods can easily predict 
the lack of an antigen and thus, the risk of an individual to become 
immunized. We examined the prevalence and risk factors for 
HIA alloimmunization in patients at risk based on genotyping 
results. Genotyping using a molecular method (HEA BeadChip™, 
Immucor, Warren, NJ) was performed on all patient specimens 
referred for molecular testing over 45 months; serologic and 
clinical data were analyzed. We used simple and multiple logistic 
regression to model the risk factors for alloimmunization to an 
HIA. Of the 2591 patients genotyped, 32 (1.2%) were homozygous 
for at least one variant predicting absence of an HIA. Of these 
32 patients, prior transfusion or pregnancy history was available 
for 29 (91%). Four susceptible patients made an antibody to an 
HIA (12.5% of all, 13.8% of those with a documented exposure). 
Two of these four patients (50%) had made an alloantibody to 
another antigen. The odds of forming an antibody to an HIA were 
not related to the total number of transfusions (p = 0.47), the 
total number of alloantibodies (p = 0.61), or diagnosis of sickle 
cell disease (p = 0.77) in simple logistic regression. Adjustment 
for the other two variables in a multiple logistic regression 
was also not significant for each variable (p = 0.6, p = 0.7, and 
p = 0.7, respectively). Although they had a known exposure to 
alloantigens through transfusion or pregnancy, 86.2 percent of 
patients (25 of 29) at risk for alloantibody formation to an HIA in 
fact did not mount an immune response to that antigen. Possible 
risk factors including the number of transfused units or the total 
number of alloantibodies made were not predictors of making 
an alloantibody to an HIA in our sampling. Our results suggest 
that other patient-specific risk factors for alloimmunization exist. 
Immunohematology 2017;33:9–14.
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Before the use of molecular technology, the detection of 
patients who are negative for high-incidence antigens (HIAs) 
remained largely impractical until these patients developed an 
antibody with HIA specificity. The development of multiplexed 
molecular platforms has uncovered a hidden population of 
patients at risk for alloimmunization against HIAs before 
any such antibodies are formed or detected.1 By definition, 
high-incidence blood group antigens occur in greater than 
99.9 percent of all individuals.2 The rare individuals who 
lack these HIAs are at risk for alloimmunization. Serologic 
detection of “HIA-negative” donors or patients (expected, by 
definition, to constitute 0.1% of the general population) is not 
a routine practice due in part to scarce reagents and resources. 
Obtaining rare donor red blood cell (RBC) units for supportive 
therapy for patients with an antibody to an HIA can cause 
serious transfusion delays because of the rarity of suitable 
donors, making transfusion management for these patients an 
ongoing challenge.3,4 If alloimmunization to an HIA does occur, 
a rare unit request to the local blood supplier and possibly to 
the American Rare Donor Program (ARDP) may be required. 
Although programs such as the ARDP have reported to fill 92 
percent of requests for an HIA-negative component,3 the need 
to request it from such a specialized agency rather than fill the 
request from units in available hospital inventory necessarily 
delays transfusion.
Beyond a delay in transfusion, the clinical relevance of 
alloimmunization to HIAs differs according to the specific 
antigen. Many alloantibodies to HIAs can cause serious 
clinical complications such as hemolytic disease of the fetus 
and newborn and transfusion reactions, as has been reported 
with antigens included on multiplexed molecular platforms 
such as k, Kpb, Jsb, U, Lub, Dib, Coa, Joa, Hy, and Lwa.5 Although 
some in vitro methods have been developed to attempt to 
predict the clinical significance of a particular alloantibody in 
vivo (such as the monocyte monolayer assay), it is difficult to 
reliably predict the clinical importance of a given alloantibody 
in a given patient.6 Consequently, avoidance of alloantigens in 
transfused components has been the mainstay for improving 
transfusion safety in alloimmunized patients. In the responder/
non-responder model of alloimmunization,7 individuals who 
have made an alloantibody to an HIA have demonstrated 
that they are an alloimmune “responder” and thus may be at 
higher risk of forming antibodies to the other common RBC 
antigens for which they are antigen-negative. Our institutional 
policy is to phenotype-match all alloimmunized patients for 
a full panel of clinically significant antigens for prophylaxis 
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in addition to their specific antigen-negative requirements; 
thus, the formation of an antibody to a single HIA renders 
the rare blood request for that patient even narrower because 
of the requirement for extended matching to the full panel of 
antigens.8
Alloimmunization to RBC antigens is a complex process 
that is incompletely understood.9 Many factors have been 
suggested that may influence alloimmunization risk, including 
genetic predisposition,7 mismatch between donor and recipient 
ethnicity,10–12 class of antigen,13 transfusion intensity,14,15 clinical 
immune modulation,16 and intervals between transfusions.12 
Despite conflicting data on risk factors for alloimmunization, 
the current paradigm requires, at minimum, that a recipient 
must be antigen-negative and exposed to an alloantigen for 
immunization to occur. The probability of exposure to HIA-
positive RBCs when transfusing units found in a typical 
hospital inventory is very high. We exploited this previously 
hidden HIA-negative transfused patient population to study 
risk factors for alloimmunization in general, since these 
patients met the minimum criterion of being antigen-negative, 
but were likely to have been transfused with antigen-positive 
blood.
We selected a panel of HIAs that were available on 
our genotyping platform to model the risk factors for 
alloimmunization in transfused patients who are negative for 
at least one HIA and therefore at risk for alloimmunization 
to that HIA. We examined the clinical and serological data 
of patients who are negative for HIAs and used simple and 
multiple logistic regression modeling techniques to estimate 
the risk of alloimmunization based on diagnosis, number of 
transfusions, and total number of detected alloantibodies.
Materials and Methods
Study Population
EDTA-preserved blood samples were obtained from July 
2009 to March 2013 from 2591 patients who had samples 
referred for molecular testing at our transfusion medicine 
reference laboratory. Referral criteria according to institutional 
standard operating procedures were specimens submitted to 
the transfusion medicine laboratory that demonstrated any 
alloantibody (including those of inconclusive specificity) or 
warm- or cold-reactive autoantibody on immunohematology 
screening, selected specimens submitted for a suspected 
delayed serologic or hemolytic transfusion reaction, or 
specimens from all patients with a diagnosis of sickle cell 
disease (SCD) or from potential bone marrow transplant 
donors for a patient with SCD. We have identified patients who 
were negative for the following HIAs: k, Kpb, Jsb, U, Lub, Dib, 
Coa, Joa, Hy, LWa, or Sc1.
Genotyping and Phenotyping 
An automated DNA extractor (QIAcube, QIAGEN, 
Inc., Germantown, MD) was used to extract the DNA, 
and genotyping was performed to predict RBC antigens 
using a molecular method (HEA BeadChip™, BioArray 
Solutions, Immucor, Warren, NJ) according to manufacturer 
instructions. Alloimmunization status was performed using a 
two-cell antibody screen by a solid-phase method (Capture-R 
Ready Screen 2, Immucor, Norcross, GA) on an automated 
analyzer (Galileo, Immucor) at the time of sample processing, 
according to institutional standard operating procedures. 
Patients were categorized as alloantigen responders if they had 
ever demonstrated an antibody to any RBC antigen.
Data Extraction
Using a search engine–created database (Phetch, 
Immucor), we retrospectively chose patients who were 
negative for an HIA from July 2009 to March 2013. Additional 
clinical information including transfusion history (continuous 
variable measured as number of RBC units transfused), 
alloimmunization status (continuous variable measured as 
number of alloantibodies), and patient diagnosis (dichotomous 
variable measured as SCD vs. other diagnosis) were obtained 
using the internal computerized medical record, and 
specimens were anonymized for analysis. The outcome was 
alloimmunization to an HIA (measured as a dichotomous 
variable).
Statistical Analysis
We performed a retrospective cohort study and used 
simple and multiple logistic regression and exact methods 
(STATA, Statacorp, College Station, TX) to model the risk 
factors for the outcome of HIA alloimmunization status 
(dichotomously as responder vs. non-responder) in this 
susceptible and highly transfused group. Logistic regression 
modeling, which is a common method in risk factor analysis 
and is particularly useful in genetic epidemiology, was used 
because we were evaluating a dichotomous outcome (responder 
vs. non-responder) and considering explanatory variables that 
were both continuous and categorical. The multiple logistic 
regression model included diagnosis, number of transfusions, 
and total number of alloantibodies as covariates (which allow 
adjustment for variables included in the model), and the 
simple logistic regression evaluated each of these variables 
individually.
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Results
A total of 2591 patients were genotyped (Table 1). Only 
32 (1.2%) of these patients were predicted to be antigen-
negative for one HIA because of homozygosity for a low-
frequency variant, consistent with the definition of an HIA. 
Transfusion and pregnancy history was obtained for 29 of 
the 32 (91%) patients. These data were abstracted from the 
patients’ medical records at our institution, so data may be 
limited for any patients who received care at other institutions. 
Eight (25%) patients were negative for more than one HIA, six 
were negative for both Hy and Joa in the Dombrock system, 
and two were negative for both Joa and U in the Dombrock 
and MNS systems, respectively (Table 2). Four patients made 
an antibody to an HIA (12.5% of all 32 patients; 13.8% of 
patients with a documented exposure). Therefore, 25 (86.2%) 
of the 29 patients who were at risk of HIA alloimmunization 
did not form an alloantibody, despite significant RBC 
exposure in this group (range of RBC units transfused was 
1–521 units, mean 51.8 units, median 19 units). One of eight 
Js(b–) patients demonstrated anti-Jsb, and three of seven U– 
patients developed anti-U (Table 2). Our HIA panel included 
two antigens encoded by the same gene, specifically Hy and 
Joa, which are single-nucleotide polymorphisms (SNPs) in 
the ADP-ribosyltransferase 4 (ART4), responsible for the 
Dombrock blood group.  
Two other patients were negative for two HIAs that are 
encoded by separate genes and separate chromosomes: U is 
encoded by glycophorin B (GYPB) on chromosome 4 and Joa 
in ART4 on chromosome 12. Two of the four patients with 
antibodies to HIAs (50%) had alloantibodies to other blood 
group antigens. Two patients had no antibody screen data 
available. Using simple logistic regression on the 29 patients 
with complete data, the odds of forming an antibody to an 
HIA were not related to the total number of transfusions 
(p = 0.47), the total number of alloantibodies found (p = 0.61), 
or diagnosis of SCD (p = 0.77). Adjustment for each of these 
variables in a multiple logistic regression model including all 
three covariates was not significant for any variable (p = 0.6, 
p = 0.7, and p = 0.7, respectively).
Discussion
Determining alloantigen exposure to so-called minor 
RBC antigens in transfused populations is challenging, 
because blood components are not routinely phenotyped or 
genotyped beyond ABO and D; similarly, most recipients are 
Table 1. Description of the study population tested by HEA 
BeadChip
Variable
Number of patients  
(N = 2591) %
Female 1649 63.6
Patients with sickle cell disease 406 15.7
Female 243





Warm autoantibodies only 77 3.0








Table 2. HIA-negative patients with and without HIA alloantibodies
By patient, allowing for individuals to be negative for multiple HIAs
Rare RBC antigen 
phenotype
Number of patients 
with rare type
Number of patients 
with alloantibody 
to HIA
Number of patients 
with other 
alloantibody(ies) (%)
k− 1 0 1 (100)
Js(b–) 8 1 8 (100)
U– 5 2 4 (80)
U–, Jo(a–) 2 1 2 (100)
Co(a–) 2 0 2 (100)
Lu(b–) 1 0 1 (100)
Hy–, Jo(a–) 6 0 5 (83)
Jo(a–) 7 0 5 (71)
Total 32 4 28
By antigen, only for consideration of immunogenicity
Rare RBC antigen 
phenotype
Number of patients 
with rare type










HIA = high-incidence antigen; RBC = red blood cell. 
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not phenotyped or genotyped for these additional antigens. 
We therefore selected a group of patients known to be negative 
for an HIA because any transfusion or pregnancy exposures 
experienced by this group would, by definition, have a greater 
than 99 percent chance of exposing them to a foreign antigen, 
compensating for the fact that minor antigen data were not 
directly available for each transfused unit or for each fetus. To 
best model the problem of alloimmunization to RBC antigens, 
it is important to characterize at-risk patients (e.g., to define an 
antigen-negative population), gather exposure details, and test 
for antibodies post-exposure. Our approach has included all of 
these important variables.
In our study, 25 (86.2%) of the 29 patients with known, 
documented exposure to foreign antigens from RBC trans-
fusion or pregnancy failed to produce an antibody to an HIA. 
Because our study population was drawn from those patients 
who were referred for molecular testing and our indications for 
referral included identification of any RBC alloantibody, it is 
not surprising that 27 of 32 (84%) of our HIA-negative group 
had at least one alloantibody and would be characterized as 
alloimmune “responders.” Although this selection bias is a 
limitation of our study, even in a population so enriched for 
alloimmune responders, we still found that 86 percent of 
HIA-negative patients were actually tolerant to HIA exposure. 
Details of the four HIA responders (Table 3) reveal that they 
were female, only one had SCD, and two of them lacked other 
RBC alloantibodies other than that to the HIA. Unfortunately, 
because 100 percent of the HIA-alloimmunized patients were 
all female, we could not include gender in our regression 
models. Only 63.6 percent of our total sample was female, but 
these proportions are not statistically significantly different 
in this sample (χ21, p = 0.13), likely attributable to the wide 
sampling error because of the rarity of HIA alloimmunization 
in the cohort.
Ten patients who were negative for an HIA had SCD, 
five of whom also had either previous history of an antibody 
or developed additional antibodies at our institution. Our 
regression models did not support SCD as a risk factor for 
alloimmunization in our cohort. One strength of regression 
modeling is the ability to adjust for multiple possible 
covariates or confounders by comparing risk estimates used 
in a multiple variable approach to those obtained using a 
simple regression model that only evaluates a single variable 
at a time. We exploited these features of regression analysis 
to allow consideration of three important putative explanatory 
variables: the total number of transfusions, the total number 
of alloantibodies, and the diagnosis of SCD. We selected 
these three attributes as possible risk factors based on a 
combination of biological plausibility or prior epidemiologic 
evidence. The number of prior transfusions is an appealing 
potential risk factor for alloimmunization because the notion 
of repeat immune stimulation to generate strong humoral 
responses is a well-known phenomenon that is exploited in 
vaccination, where a schedule of repeated exposures is routine. 
The total number of alloantibodies may be a risk factor for 
HIA alloimmunization because it reveals that a patient has 
the capability to respond to other RBC antigens. Last, we 
selected SCD diagnosis as a possible HIA alloantibody risk 
factor because other investigators have reported high rates of 
alloimmunization in this patient population.11
There was no increased risk of alloimmunization to HIAs 
according to the three important putative risk factors in our 
study; therefore, these factors do not satisfactorily explain 
the variation in alloimmunization risk that we observed in 
our patient cohort. To therefore identify risk factors that may 
explain this variation, future work includes expanding our 
study to include additional patient-specific risk factors other 
than the three we examined here. Additional risk factors for 
consideration in future modeling could include patient gender 
(which we could not model explicitly in this small study because 
all four patients who experienced the HIA alloimmunization 
event were female, and therefore there was no variation in that 
attribute), independent indicators of a proinflammatory state 
at the time of transfusion, markers of immune tolerance such 
as regulatory T-cell development, polymorphisms in genes 
related to innate or humoral immunoregulation, age of blood 
component transfused, or blood donor attributes, among a 
host of other creative hypotheses.
Table 3. Summary of patients with alloantibodies to HIAs
Patient Age (years) Gender RBC antigen phenotype Antibody to HIA Diagnosis Other antibodies
History of RBC 
transfusion
1 78 F Js(b–) Anti-Jsb Renal failure Anti-C, -E, -Jka Multiple
2 28 F U– Anti-U Pregnancy None Unknown
3 40 F U– Anti-U Sickle cell disease Anti-D, -C, -E, -Fya, -Jkb, -Lea Multiple
4 30 F U–, Jo(a–) Anti-U Pregnancy None None
HIA = high-incidence antigen; RBC = red blood cell.
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Seven of the 15 patients who were Jo(a–) had developed 
an inconclusive reactivity that could suggest the potential to 
form an antibody to an HIA, but because these antibodies 
did not demonstrate conclusive reactivity, these patients 
were scored in our study as non-responders to HIAs. This 
conversion from an inconclusive to a potential antibody to 
an HIA could represent early anamnestic response.11 We 
also included the number of transfused packed RBC units 
in our model, but this variable was not associated with 
alloimmunization to HIAs in our sample in either simple or 
multiple logistic regression analyses. On further review, one 
Jo(a–) patient received a total of 521 RBC units and still was 
not immunized to this antigen, demonstrating the complexity 
of the immune response despite intense exposure. The extent 
to which differential immunogenicity across RBC antigens is 
responsible or contributing to the tolerance to HIAs that we 
observed is difficult to quantify.
Immunogenicity has been described on a population level 
by dividing the probability of an antigen-positive donor by 
the probability that an individual recipient may be antigen-
negative, as described by Giblett’s equation17 and modifications 
thereof, to include phenomena such as evanescence.13 
Attempts to calculate immunogenicity using these methods for 
HIAs necessarily results in extremely low “potency,” because 
the probability of being antigen-negative (which is near 0) is 
divided by the probability of exposure (near 1), so the product is 
near 0. For an individual patient, however, such as any of those 
who were HIA-negative in our study, the probability of being 
antigen-negative is 1 (because it was empirically determined) 
and the probability of exposure to an antigen-positive unit 
remains at nearly 1, so immunogenicity by Giblett’s method 
would be near 1, which is not consistent with our data. 
Therefore, we suggest that some other biological processes 
are likely contributing to immunogenicity of HIAs that are 
not captured in the population-based estimates developed 
by Giblett. Further research on membrane biochemistry, 
including antigen density or processing and presentation of 
HIAs in antigen-presenting cells, may help clarify some of this 
unclear biology.
We were unable to identify a risk factor associated with HIA 
alloimmunization in our study. If the transfusion community 
could identify specific risk factors associated with an increased 
risk of alloimmunization to HIAs or other RBC antigens, 
there would be important implications for clinical transfusion 
medicine practice, particularly in terms of triaging rare blood. 
If one could reliably predict the alloimmune responders, then 
perhaps we could confidently transfuse the remaining patients 
with HIA-positive blood and reduce transfusion delays 
without compromising transfusion safety. Until then, there is 
still an important role for routine donor genotyping to include 
testing to predict HIAs to provide antigen-negative blood. 
An important strength of our approach is that we 
characterized at-risk, antigen-negative recipients with known 
exposures to foreign antigens. Alloimmunization to the HIAs 
defined in this study is uncommon even in patients who have 
been heavily transfused. Although they had a known exposure 
to allogeneic blood through transfusion and/or pregnancy, 
86.2 percent of patients at risk for alloimmunization to an HIA 
in fact did not mount an immune response to that antigen. 
Possible risk factors for alloimmunization, including the 
number of RBC units transfused, SCD, or the total number 
of antibodies formed, were not predictors for making an 
antibody to an HIA in our study. Differential immunogenicity 
of the HIAs based on mechanisms or properties that have not 
been characterized may contribute to the high tolerance we 
observed, but our results more generally support the notion 
that other patient-specific risk factors for alloimmunization, 
such as a genetic basis to a “responder” phenotype, exist.
References
 1. Hashmi G, Shariff T, Seul M, et al. A flexible array format 
for large-scale, rapid blood group DNA typing. Transfusion 
2005;45:680–8.
 2. Telen MJ, Rosse WF, Parker CJ, Moulds MK, Moulds JJ. 
Evidence that several high-frequency human blood group 
antigens reside on phosphatidylinositol-linked erythrocyte 
membrane proteins. Blood 1990;75:1404–7.
 3. Meny GM, Flickinger C, Marcucci C. The American Rare Donor 
Program. J Crit Care 2013;28:110.e9–18.
 4. Seltsam A, Wagner FF, Salama A, Flegel WA. Antibodies 
to high-frequency antigens may decrease the quality of 
transfusion support: an observational study. Transfusion 
2003;43:1563–6.
 5. Reid ME, Lomas-Francis C, Olsson ML. The blood group 
antigen factsbook. 3rd ed. San Diego, CA: Academic Press, 
2012.
 6. Leger RM. In vitro cellular assays and other approaches used 
to predict the clinical significance of red cell alloantibodies: a 
review. Immunohematology 2002;18:65–70.
 7. Higgins JM, Sloan SR. Stochastic modeling of human RBC 
alloimmunization: evidence for a distinct population of 
immunologic responders. Blood 2008;112:2546–53.
 8. Karafin MS, Shirey RS, Ness PM, King KE. Antigen-matched 
red blood cell transfusions for patients with sickle cell disease 
at The Johns Hopkins Hospital. Immunohematology 2012;28: 
3–6.
 9. Zimring JC, Welniak L, Semple JW, et al. Current problems and 
future directions of transfusion-induced alloimmunization: 
summary of an NHLBI working group. Transfusion 
2011;51:435–41.
 10. Price CL, Johnson MT, Lindsay T, Dalton D, Watkins AR, 
DeBaun MR. The Sickle Cell Sabbath: a community program 
14 IMMUNOHEMATOLOGY, Volume 33, Number 1, 2017
P.A.R. Brunker et al.
increases first-time blood donors in the African American faith 
community. Transfusion 2009;49:519–23.
 11. Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, 
Lubin B. Alloimmunization in sickle cell anemia and transfusion 
of racially unmatched blood. N Engl J Med 1990;322:1617–21.
 12. Urbaniak SJ. Alloimmunity to human red blood cell antigens. 
Vox Sang 2002;83(Suppl 1):293–7.
 13. Tormey CA, Stack G. Immunogenicity of blood group antigens: 
a mathematical model corrected for antibody evanescence 
with exclusion of naturally occurring and pregnancy-related 
antibodies. Blood 2009;114:4279–82.
 14. Zalpuri S, Middelburg RA, Schonewille H, et al. Intensive 
red blood cell transfusions and risk of alloimmunization. 
Transfusion 2014;54:278–84.
 15. Zalpuri S, Zwaginga JJ, le Cessie S, Elshuis J, Schonewille H, 
van der Bom JG. Red-blood-cell alloimmunization and number 
of red-blood-cell transfusions. Vox Sang 2012;102:144–9.
 16. Zalpuri S, Evers D, Zwaginga JJ, et al. Immunosuppressants 
and alloimmunization against red blood cell transfusions. 
Transfusion 2014;54:1981–7.
 17. Giblett ER. A critique of the theoretical hazard of inter vs. intra-
racial transfusion. Transfusion 1961;1:233–8.
Patricia A.R. Brunker, MD, MHS, DPhil(Oxon), FCAP (corresponding 
author), Assistant Professor, Department of Pathology, Division of 
Transfusion Medicine, The Johns Hopkins School of Medicine, 1800 
Orleans Street, Sheikh Zayed Tower, Rm. 3081, Baltimore, MD 21287, 
pbrunke1@jhmi.edu; Keerthana Ravindran, BS, MLS(ASCP)SBB, 
Clinical Laboratory Scientist III, Department of Pathology, Division 
of Transfusion Medicine, The Johns Hopkins Hospital; and R. Sue 
Shirey, MS, MT(ASCP)SBB, Technical Specialist II, Department of 
Pathology, Division of Transfusion Medicine, The Johns Hopkins 
Hospital, Baltimore, MD.
Immunohematology is on the Web!
www.redcross.org/about-us/publications/
immunohematology
For more information, send an e-mail to  
immuno@redcross.org.
For information concerning the National Reference 
Laboratory for Blood Group Serology, including the American 
Rare Donor Program, contact Sandra Nance, by phone at 
(215) 451-4362, by fax at (215) 451-2538, or by e-mail at 
Sandra.Nance@redcross.org.
Important Notice About Manuscripts for 
Immunohematology
Please e-mail all manuscripts to immuno@redcross.org.
Attention: SBB and BB Students
You are eligible for a free 1-year subscription to 
Immunohematology.
Ask your education supervisor to submit the name and 
complete address for each student and the inclusive dates 
of the training period to immuno@redcross.org.
Free Classified Ads and Announcements
Immunohematology will publish classified ads and announcements (SBB schools, meetings, symposia, etc.) without charge.
E-mail information to immuno@redcross.org or fax to (215) 451-2538
